BigHat Biosciences develops antibody and protein therapeutics using machine learning, synthetic biology, and automated experimentation.
BigHat Biosciences has raised $75.0M in total funding. The most recent round was Series C. The last funding was announced in September 2026.
BigHat Biosciences's investors include Andreessen Horowitz, S32, Catalio Capital Management, Eli Lilly, 8VC.
BigHat Biosciences is headquartered in San Mateo, United States.
BigHat Biosciences develops antibody and protein therapeutics using machine learning, synthetic biology, and automated experimentation.
BigHat Biosciences is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BigHat Biosciences — Funding & Investors." VCBacked, September 24, 2026, https://www.vcbacked.co/company/bighat-biosciences. Accessed October 17, 2026.
VCBacked. (2026). BigHat Biosciences — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/bighat-biosciences
{{cite web |title=BigHat Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/bighat-biosciences |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated